A Guide to Biomarker Validation
18 min read · Updated June 2026
Key Takeaways
- Biomarker validation is not a single step - it spans five stages from Research Use Only through post-market surveillance, each requiring different levels of evidence depending on intended use and patient risk
- The global biomarker market was valued at $62 billion in 2025 and is projected to reach $104 billion by 2030 - but the translation rate from discovery to clinical use remains a critical bottleneck
- Effective validation requires defining intended use early, planning for diversity and inclusivity in study populations, and leveraging AI-driven analytics to accelerate the process without compromising rigour
Jump to section
The potential for the use of biomarkers in early disease detection, drug development and precision medicine is undeniable. It's no surprise that the area has generated a rapidly-growing market, with more than a million scientific papers - over half of them published in the last decade - and a global market valued at $62 billion in 2025, projected to reach $104 billion by 2030 (MarketsandMarkets, 2025).
Much biomedical research is now focused on biomarker discovery and validation, searching for predictive, prognostic, or safety biomarkers across various biological sample types and analytical approaches. Many candidates have been identified that can be used for both early diagnosis and therapeutic guidance in cancer, heart disease, Alzheimer's disease, rheumatoid arthritis, and asthma.
Perhaps the most notable recent success story in precision medicine is in relation to the biomarker human epidermal growth factor receptor 2 (HER2). HER2 is associated with a poor prognosis in human breast cancer. Patients expressing high levels of HER2 have had HER2-targeted therapy available for over two decades. Results from the recent DESTINY-Breast04 study (NCT03734029) showed patients with low levels of HER2 treated with fam-trastuzumab deruxtecan-nxki (T-DXd) had a two-fold increase in progression-free survival, regardless of hormone receptor status - implying a shift in how HER2 status is categorized and dramatically expanding the patient population who could benefit.
To see more successes such as this, we need to speed up the translation rate into clinical use and reduce the failure rate associated with biomarkers while maintaining ethical and efficient procedures. Tackling validation correctly is one of the most important ways to achieve that. This article outlines the key validation stages and considerations for risk mitigation in the validation process, providing strategies for moving forward confidently in the product development life cycle.
What Does 'Biomarker Validation' Actually Mean?
In its simplest form, biomarker validation is the determination that the performance of the discovered biomarker is credible. It is a process to determine how well it measures, represents and/or predicts something else. There are many different aspects to consider when attempting to validate - there isn't a 'one-size-fits-all' guide on how to achieve it.
The intended use guides the appropriate level of validation. A higher degree of validation evidence is required from biomarkers that pose a greater risk and/or have greater patient consequences. Effective validation therefore requires that the intended use is clearly established.
This work sits at the heart of what Sonrai supports - from the analytical tools that power discovery through to the governed research environment that makes validation evidence reproducible and audit-ready. See how this plays out in our Target ID & Validation and Translational Analytics capabilities.
Defining the Intended Use
Even at the early stages of development, an attempt should be made to outline a product's intended use statement - addressing the points below while acknowledging known gaps, and updating it based on evidence as the product development life cycle progresses:
- Intended patient population
- Test purpose and what the results will inform
- Type of patient specimen required for testing
- Intended user of the test
- Benefit and risks to patients
- Contraindications
- Whether there is an associated medicinal product or product group
- Testing delivery model (local vs central)
Validation Planning
Planning early for a robust validation will help you move efficiently forward when the time is right.
Biomarker Validation Readiness
A biomarker is ready for validation when:
- It measures an objective, quantifiable characteristic successfully
- It correlates strongly with the clinical endpoint within the intended use population
- Its performance is reproducible in independent test cohorts
Scope and Scale of Validation
- Novel vs established biomarker
- Current gold standard or state of the art
- Observational vs interventional vs commercial use
- Geographical regions of use and regulator jurisdiction
- Patient risk/benefit ratio associated with its introduction to clinical use
- Performance claims must be supported with sufficient evidence
Practical Considerations
- Selection of an analytical platform suitable for the intended use
- Appropriateness of supply, quality and/or commercialisation agreements
- Availability of samples representative of the intended patient population
- Ensuring diversity and inclusivity in the patient population
- Sample collection, storage and stability
- Inclusion of appropriate positive and negative controls
- Study design to minimize bias or confounding variables
- Ensuring statistical power when necessary
- Data management planning
Target ID & Validation
See how Sonrai supports the analytical validation of biomarker candidates, from integrating public and internal data through to reproducible evidence generation.
The Biomarker Validation Process
1. Analytical Method Development and Research Use Only (RUO) Validation
Once performance is demonstrated as reproducible in relevant independent data sets, and the intended use has been defined, a test method is developed that initiates the process of transitioning a discovered biomarker into an in vitro diagnostic (IVD) product. The real-world implementation is a critical factor as the chosen method will impact the accessibility of the product to the market.
Although not essential, including a Research Use Only (RUO) phase can be beneficial. There is no regulatory standard for this stage. RUO validation studies are typically much smaller in scope and scale than those required for an interventional or commercial product.
Things to consider: The technologies available, the most appropriate technology, and the time and cost investment. The advantage of an RUO phase is that it allows decisions to be made on whether to move forward or pause while in a relatively low-cost phase. The further into the validation process, the more investment is required.
2. Retrospective Clinical Validation
Like the previous stage, retrospective clinical validation is not strictly essential but provides the opportunity to collect additional evidence about the performance of the biomarker within purpose-designed testing parameters and to identify potential areas of weakness in test delivery that can be addressed ahead of the next stage.
Things to consider: There are different ways to approach retrospective clinical validation. Where the option is available, collecting patient samples within a clinical trial for retrospective or observational analysis is a great way to assess performance. Alternatively, acquiring a representative clinical study sample cohort for analysis will provide valuable additional evidence on performance and could be a faster way to advance.
3. Analytical Validation Suitable for Investigational Use in a Clinical Trial
Where a biomarker is to be used for a medical purpose but is not yet approved for marketing, it is normally termed 'investigational use only' (in the US) or 'device for performance evaluation' (in the EU). This stage typically involves one or more clinical studies using the biomarker to inform patient treatment decisions. As such, the risk to patients must be carefully considered.
The applicable regulations in the countries where it will be tested also influence manufacturer decisions. For example, testing of US patient samples must comply with CLIA and FDA IDE requirements, or for EU studies, approval to proceed will require manufacturers to satisfy the Notified Body of conformity to the EU IVDR.
Things to consider:
- Patient sample matrix stability and impact on shipping and storage conditions
- Performance limits obtained during this stage should be used to monitor performance during the clinical study
- If used for screening or enrollment decisions, the turnaround time to results should be as short as possible
- Manufacturers may wish to use resulting clinical trial data to support marketing approval - minimising further development from this stage de-risks downstream bridging studies
Patient Stratification
Biomarker-guided patient stratification in clinical trials requires the same rigorous validation foundation described here. See how Sonrai supports that process.
4. Validation Suitable for Marketing Approval
The level of evidence required to demonstrate the performance and safety of the biomarker device is related to the device safety classification relevant to the regulatory jurisdiction(s) of the countries in which the device is intended to be marketed.
This stage incorporates clinical validation which assesses the sensitivity and specificity of the biomarker to identify, measure or predict the clinical outcome it is intended to reflect. Sensitivity refers to the rate of true positive findings; specificity is associated with the rate of true negative findings.
Clinical studies (FDA term) or interventional clinical performance evaluation studies (EU term) are necessary in the case of novel biomarkers for which the manufacturer must demonstrate safety and effectiveness. Where a predicate device to which equivalence can be demonstrated exists, such studies may not be essential - in the case of a 510(k), evidence from a retrospective evaluation is normally sufficient.
Things to consider: The commercial test delivery model (central lab test vs distributed kit) will impact the analytical validation requirements. To include process validation, evidence of sample, intermediate and reagent stability, and guard banding studies is required.
5. Post-Market Surveillance
Post-market surveillance is the systematic collection and analysis of use and performance data for medical devices. All medical devices (including in vitro diagnostics in the field) must be monitored by the manufacturer for the full device life span. Data is collected directly from users via proactive (feedback, questionnaires and literature searches) and reactive channels (complaint handling).
Analysis of the data enables manufacturers to identify any change to the expected occurrence of device issues, early identification of unforeseen hazards and vulnerabilities, use errors or off-label use. An output will be an affirmation of the devices benefit-risk profile and/or identification of any device changes needed to maintain that profile.
Looking to the Future
A modern approach to validation should improve on the systematic evaluation of the evidence and on promoting, from each translational step to the next, the biomarkers that have the best evidence and can be the eventual winners.
Strategising Across the Biomarker Ecosystem
This requires a strategy to coordinate the wider research agenda and a fostering of international multiteam collaborations rather than fragmented efforts of small, opportunistic studies. The Early Detection Research Network has developed valuable specimen reference sets that can be used by multiple labs for biomarker validation and is an excellent example of this collaborative approach.
Expanding Horizons to Encompass New Methods
By continuing to evolve current thinking about biomarkers, endpoints, and other tools, we will accelerate our understanding of biological science and improve the efficiency and pace at which effective treatments are developed. The evolution of biomarker science applies not only to the technical side of research but also to the human element - in the form of much greater awareness and proactivity towards inclusion and diversity in clinical research.
The coronavirus pandemic highlighted the impact of healthcare inequalities. It wasn't until 1993 that it became law (in the US) to include women in clinical research. A recent study highlighted that 80% of cancer patients received care in community hospitals that lacked the facilities or expertise to implement precision medicine. More work is needed to address these gaps.
Nowadays, new high-throughput technologies have exploded the potential of biomarker research, and increased computer processing power has fuelled the development of methodological strategies based on artificial intelligence. Knowledge extraction from big data is generating a new paradigm for AI-guided discovery and therapy - particularly important when assessing complex and composite biomarkers, where the interrelationships of multiple biomarkers must be considered simultaneously. Free bioinformatics tools can help researchers get started, but AI-driven platforms are increasingly essential for managing the full complexity of validation at scale.
Useful Resources
- The FDA makes the Summary of Safety and Effectiveness Data (SSED) of all approved tests available to the public. Example: SSED for the original HercepTest, a semi-quantitative immunohistochemical assay to determine HER2 overexpression in breast cancer tissues.
- The EU IVDR provides the information needed to comply for manufacturers, authorised representatives, importers or distributors of IVDs in the EU.
- Recommendations on using Guidance Documents Related to the MDR and IVDR - MedTech Europe guidance for manufacturers on meeting IVDR requirements.
- The Clinical and Laboratory Standards Institute (CLSI) provides guidelines and standards for testing biomarker assays' quality, safety, and efficiency.
- The FDA Bioanalytical Method Validation guidance document provides information for validating bioanalytical methods used in pre-clinical and clinical research.
- Guidance for Industry and FDA Staff: In Vitro Diagnostic Device Studies - Frequently Asked Questions
No cost. No risk.
Ready to accelerate your biomarker validation?
Challenge Sonrai to find what others haven't. We'll apply our analytical platform to your biomarker data - at no cost.
Explore the free showcaseRelated Reading
Article
18 Free Bioinformatics Tools for Biomarker Discovery
Case Study
Predictive Biomarker Discovery
Article
The Future of Biomarkers
Talk to our team
Sonrai acts as an extension of your team, combining scientific expertise, transparent and reproducible analysis, and a governed research environment to generate decision-ready evidence that can be revisited, reproduced, and built upon throughout the life of a programme.
Book a demo


